Evaluating the Use of Artificial Intelligence to Improve Family Conversations for Intensive Care Patients and Their Families
Launched by DAVY VAN DE SANDE · Jan 2, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how artificial intelligence (AI) can help improve conversations between doctors and families of patients in the intensive care unit (ICU). Right now, doctors spend a lot of time writing notes after talking with families, which can take time away from caring for patients. The trial will see if AI can quickly create easy-to-understand summaries of these conversations, making it easier for doctors to document and for families to grasp important medical information.
To participate in the study, families must have a loved one admitted to the adult ICU, and all family members involved in the conversation must be 18 years or older and able to speak Dutch. All participants, including family members and healthcare professionals, will need to sign consent forms to take part. If you decide to participate, you can expect to be part of a conversation where the AI helps summarize what is discussed, potentially making it less stressful and more informative for everyone involved.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Informed-consent is signed by all participating family members during the conversation.
- • Informed-consent is signed by the ICU healthcare professionals.
- • The patient of the family must be admitted to the adult ICU.
- • All participating family members must be 18 years or older.
- • The family conversation must be in Dutch.
- Exclusion Criteria:
- • Trained to interpret medical jargon and/or intensive care terminology specifically
- • Difficulty reading and/or writing in the Dutch language
About Davy Van De Sande
Davy van de Sande is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a focus on rigorous scientific methodology and ethical standards, Davy leads initiatives that encompass a wide range of therapeutic areas, ensuring comprehensive trial design and execution. Collaborating with leading healthcare professionals and institutions, Davy is dedicated to fostering transparency and integrity within the clinical research landscape, ultimately contributing to the development of safe and effective treatments for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rotterdam, Zuid Holland, Netherlands
Patients applied
Trial Officials
Diederik Gommers, MD PhD
Study Director
Intensive Care Adults, Erasmus University Medical Center, Rotterdam, the Netherlands
Michel E. van Genderen, MD PhD
Principal Investigator
Intensive Care Adults, Erasmus University Medical Center, Rotterdam, the Netherlands
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported